Pymaceuticals Observable Trends

1. Of the four drugs being compared, Capomulin was the only drug to see a decrease in tumor volume over the 45 day period. Infubinol, Ketapril, and the placebo all saw increases in tumor volume over the same time period.
2. Capomulin saw the lowest increase in metastatic cancer sites over the 45 day treatment cycle compared to Infubinol, Ketapril, and the placebo, which saw larger increases.
3. Capomulin also exhibited the highest survival rate for the mice studied over the course of the 45 days.